Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
Highly active antiretroviral therapy (HAART) regimens, especially those including protease inhibitors have been shown to cause, in a high proportion of HIV-infected patients, a metabolic syndrome (lipodystrophy/lipoatrophy, dyslipidemia, type 2 diabetes mellitus, insulin resistance) that may be associated with an increased risk of cardiovascular disease. A careful stratification of the cardiovascular risk of HIV-infected patients under HAART is needed according to the most recent clinical guidelines.
Barbaro
Giuseppe
G
Department of Medical Pathophysiology, University La Sapienza, Rome, Italy. g.barbaro@tin.it
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000453:epidemiology; D050171:Dyslipidemias / Q000139:chemically induced / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000453:epidemiology; D012307:Risk Factors; D013577:Syndrome